GSK3377794

DRUG3 trials

Sponsors

USWM Ct LLC, GlaxoSmithKline

Conditions

Multiple Myeloma & other indicationsMyxoid/round cell liposarcoma (MRCLS)NeoplasmsNon-small cell lung cancer (NSCLC)Synovial sarcomaSynovial sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS)

Phase 1

Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies

RecruitingCTIS2024-513033-21-00

USWM Ct LLCMultiple Myeloma & other indications, Myxoid/round cell liposarcoma (MRCLS), Non-small cell lung cancer (NSCLC) +1

Start: 2020-09-14Target: 10Updated: 2026-01-09

Phase 2

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

WithdrawnNCT03697824

GlaxoSmithKlineNeoplasms

Start: 2019-02-25End: 2022-07-18Updated: 2019-10-29

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Active, not recruitingCTIS2024-513032-14-00

USWM Ct LLCSynovial sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS)

Start: 2020-04-21Target: 21Updated: 2025-11-24